secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-09-30T22:00:51+00:00
Accession:  0001193125-26-409335
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Sagimet Biosciences prices $115M offering: 8.75M shares at $10, 2.75M pre-funded warrants for Phase 3 acne trial
--------------------------------------------------------------------------------

- Offering: 8,750,010 shares at $10.00 and pre-funded warrants for 2,750,010 shares at $9.9999 (gross ~$115M); net proceeds ~$107.5M; close Oct 1, 2026.
- Proceeds fund Phase 3 trial of denifanstat in acne, pre-launch activities, TVB-3567 through Phase 2 topline, topical FASN inhibitor program to IND, and general corporate purposes.
- Pre-funded warrants exercisable immediately at $0.0001/share; 4.99% beneficial ownership cap (9.99% at purchaser election), adjustable to 19.99% with 61 days' notice.
- Leerink, TD Securities, Guggenheim and Oppenheimer are joint book-running managers; Canaccord Genuity, H.C. Wainwright, JonesTrading and Clear Street are co-lead managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000119312526409335/0001193125-26-409335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000119312526409335/d136610d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-409335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer